Treace Medical reports Q4 revenue $62.2M (+25% YoY), FY2023 $187.1M (+32%); guides FY2024 $220-225M

TREACE MEDICAL CONCEPTS, INC.

2023-FY EPS reported -$0.81 revenue$187,118,000

Q4 2023 revenue $62.2M, up 25% YoY; full-year revenue $187.1M, up 32%, above guidance of $182-186M.
Q4 net loss ($6.3M) ($0.10/share); full-year net loss ($49.5M) ($0.81/share); adjusted net loss same.
Active surgeons reached 2,855 (+20% YoY); direct sales reps 227 (+35% YoY).
FY2024 revenue guidance $220-225M (18-20% growth); expects ~50% improvement in Adjusted EBITDA.
Launched SpeedPlate, Micro-Lapiplasty, Hammertoe Fixation; patent portfolio 57 granted US patents.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.65

TREACE MEDICAL CONCEPTS, INC. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).

Period: the quarter and year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 27, 2024, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-021152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.